Health
CSOFT’s health blog aims to provide insight into complex diseases, treatment options and regulatory developments, and other prevalent health issues people face today.
FDA Grants LifeSignals Approval for Remote Monitoring Program
LifeSignals’ LX1550 Multiparameter Remote Monitoring Platform has been granted FDA Class II 510 (K) approval, following recent CE marketing. With the Remote Monitoring Platform, healthtech companies can improve their product and service portfolios and provide...
Canada Approves BeiGene BRUKINSA for Mantle Cell Lymphoma
Health Canada has granted BeiGene approval for BRUKINSA (Zanubrutinib) to treat mantle cell lymphoma (MCL) in adults who have already received at least one other prior treatment. As global, science-driven biotechnology company, BeiGene focuses on improving treatment...
AstraZeneca Diabetes Drug Given FDA Approval for Children
AstraZeneca has been granted FDA approval for its once-weekly diabetes medicine Bydureon (exenatide) to treat children (aged 10-18) with type-2 diabetes. The drug, an injectable suspension, aims to lower blood sugar rates. The approval is based on a late-stage study...
LATAM Series: Mexico’s Medical Device Regulatory Pathway
Our LATAM series continues this week with Mexico’s medical device regulatory pathway. In 2019, Mexico’s import medical device market was estimated to be approximately $5.7 billion USD. In 2020, that number increased to $6.5 billion USD. With demand for medical devices...
Endometrial Carcinoma: FDA Approved KEYTRUDA and LENVIMA Treatment
Merck (also known as MSD outside of North America) and Eisai Inc. announced that the FDA (Food and Drug Administration) has given approval for the combined treatment of Merck’s KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, and Elsai’s LENVIMA (lenvatinib), a...
FDA Approved Octapharma Immunoglobulin for Dermatomyositis
The FDA (Food and Drug Administration) has given Octapharma USA approval for the first-ever intravenous immunoglobulin, called Octagam 10%, to treat adult dermatomyositis. 10 out of every million people in the US live with Dermatomyositis, a rare, idiopathic...
FDA to Update Labelling on All Statins for Pregnant Patients
The US FDA (Food and Drug Administration) plans to modify labelling on all statins to change the blanketed contraindication on the drugs in all pregnant patients. Statins, a group of lipid-lowering drugs, are used to help reduce illness and mortality of patients who...
Neutrogena Beach Defense and Ultra Sheer Sunscreens Recalled
Johnson & Johnson is recalling Neutrogena Beach Defense and Ultra Sheer sunscreens after elevated levels of benzene were detected. Benzene is a chemical compound that, over long term and frequent exposure via skin contact or inhalation, can cause serious health...
IRLAB and Ipsen Form Global Exclusive Licensing Agreement for Parkinson’s Disease
Ipsen, a global pharma company, and IRLAB, a Swedish research and development business, have entered an exclusive licensing agreement for Ipsen to commercialize mesdopetam, a dopamine D-3 receptor antagonist taken orally to improve the quality of life for patients...
FDA Grants Approval to iSTAR Medical for Clinical Trial for MINIject
The U.S. Food and Drug Administration (FDA) has granted iSTAR Investigational Device Exemption (IDE) approval for to begin a trial with MINIject, a revolutionary MIGS device for patients with primary open-angle glaucoma. The study will test the safety and efficacy of...
Categories
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com